Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Cash from Investing Activities (2019 - 2025)

Avidity Biosciences' Cash from Investing Activities history spans 7 years, with the latest figure at $207.2 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 422.91% year-over-year to $207.2 million; the TTM value through Dec 2025 reached -$38.0 million, up 95.55%, while the annual FY2025 figure was -$38.0 million, 95.55% up from the prior year.
  • Cash from Investing Activities reached $207.2 million in Q4 2025 per RNA's latest filing, up from -$587.9 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $207.2 million in Q4 2025 to a low of -$587.9 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$64.7 million, with a median of -$12.7 million recorded in 2022.
  • The largest YoY upside for Cash from Investing Activities was 1466.5% in 2022 against a maximum downside of 33323.81% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$84.1 million in 2021, then surged by 90.76% to -$7.8 million in 2022, then surged by 757.05% to $51.0 million in 2023, then plummeted by 225.73% to -$64.2 million in 2024, then soared by 422.91% to $207.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Cash from Investing Activities are $207.2 million (Q4 2025), -$587.9 million (Q3 2025), and $185.5 million (Q2 2025).